Close
Close

Cell based Target Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? Work with Us FAQ

Accelerate discovery of functional antibodies against complex cell-surface targets using our developability-engineered human libraries and advanced screening platforms.

Isolate antibodies against native epitopes on GPCRs, ion channels, and multi-subunit complexes.

Advance from project design to functional IgG candidates in as little as 10 weeks.

Eliminate liabilities early with validated frameworks and multi-parameter screening.

Maximize your probability of success with great library diversity and strategic epitope binning.

Fig.1 antibody diversity. (Creative Biolabs AI)
Up to 1011 Diversity 		Fig.2 Weeks to functional leads. (Creative Biolabs AI)
Weeks to Functional Leads 		Fig.3 Validated human frameworks. (Creative Biolabs AI)
Validated Human Frameworks

Request a Quote

Optimized Solutions for Challenging Cell-Based Targets

From Vast Diversity to Functional Hits Against Native Conformations.

Conquering complex cell-surface targets demands more than just binding affinity, it requires functional outcomes. Compressed timelines and the need for highly developable candidates leave no room for error. At Creative Biolabs, our phage and yeast display platforms are tuned to traverse the vastness of our premier libraries with surgical precision.

By leveraging cell-based biopanning against targets in their native conformation, competitive and subtractive selection, and early developability triage, we systematically eliminate non-specific binders and prioritize diverse, functional candidates. This integrated approach bypasses the limitations of purified protein antigens, mitigates epitope redundancy, and delivers leads with the functional activity (agonism, antagonism, internalization), which is critical for therapeutic success and downstream validation.

Ask About Turnaround & Pricing

Workflow

Fig.4 Discovery design & antigen strategy. (Creative Biolabs AI)

Discovery Design & Antigen Strategy

Target assessment; antigen format design (live/fixed cells, complexes, soluble domains); cell line engineering/validation; decoy/competitor mapping; cross-reactivity risk plan

Fig.5 Biopanning & Enrichment. (Creative Biolabs AI)

Biopanning & Enrichment

Up to 4-5 rounds of cell-based panning; Competitive and subtractive panning; stringency escalation; off-target depletion (using parental/related cells); native conformation cell panning

Fig.6 Single-Clone Screening & Specificity De-risking. (Creative Biolabs AI)

Single-Clone Screening & Specificity De-risking

High-throughput flow cytometry or cell-based ELISA; orthogonal specificity testing (parental vs. target cells).

Fig.7 Sequence Analytics & Liability Filtering. (Creative Biolabs AI)

Sequence Analytics & Liability Filtering

NGS-driven clonotype clustering; in silico liability screens (PTMs, deamidation, aggregation); framework optimization paths.

Fig.8 Functional Selection & Epitope Strategy. (Creative Biolabs AI)

Functional Selection & Epitope Strategy

Cell-based functional assays (agonism/antagonism/internalization); epitope binning; cross-species/reactivity checks.

Fig.9 Expression, IgG Conversion & Developability Panel. (Creative Biolabs AI)

Expression, IgG Conversion & Developability Panel

Mini-panel IgG expression; solubility/stability/aggregation profiling.

Fig.10 Reporting and Deliverables. (Creative Biolabs AI)

Reporting and Deliverables

Project report; sequences and raw data access; clear next-step options.

Discuss Your Screening Strategy with an Expert

Quick Library Selector

Our premade antibody libraries are engineered for developability and breadth, optimized frameworks, rational CDR diversification, and compatibility with phage and yeast display for antibody discovery.

Human Camel Llama Alpaca Humanized VHH
Antibody Library ID Display Technology Library Format Library Size
HuScL-6
☆Highly Recommended 		pIII-fusion, Phagemid Phage Display Naïve scFv 2.1×1011
HuScL-3S pIII-fusion, Phagemid Phage Display Semi-synthetic scFv >1.0×1011
HuFabL-4 pIII-fusion, Phagemid Phage Display Naïve Fab 1.9×1010
HuFabssL-1 pIII-fusion, Phagemid Phage Display Naïve & synthetic Fab 1.8×1010

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Overcoming Challenges with Complex Multi-Pass Transmembrane Proteins
Target Category Multi-pass Membrane Proteins
Challenge The client targeted a complex multi-pass transmembrane protein critical for signaling in oncology. The project faced two major technical bottlenecks:
  • Structural Instability: The target is notoriously difficult to express and purify.
  • Epitope Authenticity: Traditional protein-based immunization or screening would yield binders that fail to recognize the protein in its physiologically active state on the cell surface.
Our Solution By leveraging our High-Diversity Premade Antibody Libraries and a proprietary Whole-Cell Biopanning platform, we bypassed the need for recombinant protein entirely.
Fig.11 Target Preparation. (Creative Biolabs AI)

Target Preparation 		We engineered a stable HEK293 cell line overexpressing the target protein, ensuring the antigen was presented in its native membrane environment.
Fig.12 Conformation-Sensitive Screening. (Creative Biolabs AI)

Conformation-Sensitive Screening 		Utilizing our premade libraries, we performed multiple rounds of whole-cell panning. We employed a subtractive screening strategy using non-transfected parental cells to deplete non-specific binders, followed by positive selection on the overexpressing line.
Fig.13 High-Throughput Validation. (Creative Biolabs AI)

High-Throughput Validation 		Individual clones were directly validated using Monoclonal Phage ELISA and Flow Cytometry (FACS) to ensure they recognized the target in its native cellular context.
Key Outcomes
Zero Protein Dependency
Successfully identified high-affinity binders without requiring a single milligram of purified protein. 		Significant Enrichment
Panning outputs showed a clear shift in binding signals, indicating a highly focused selection of target-specific clones.
Deep Clonal Insight
NGS Analysis identified 10 dominant clonal families. The high frequency of these top sequences (as shown in the distribution data) confirmed a successful convergence toward specific, high-affinity binders. 		Functional Ready
Lead candidates demonstrated potent binding in functional cell-based assays.
Representative Data
Fig.14 Case-1 ELISA and FACS results. (Creative Biolabs Original)
Fig.15 Case-1 Frequency distribution. (Creative Biolabs Original)
ELISA and FACS results for individual phage clones, showing strong binding signals to the target-overexpressing cells (Target+) compared to control cells (Target-). Frequency distribution of the top 10 antibody sequences identified by NGS post-panning. The high abundance of a few dominant clones indicates successful and specific selection.

Ready to Build Your Success Story? Contact Us

Related Services

Find additional antibody discovery services tailored to your specific needs.

Fig.16 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.17 Functional human antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.18 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.19 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.20 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.21 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Fig.22 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Need something adjacent? Request a Quote

Why Partners Trust Our Discovery Platform?

Bridging the gap between vast library diversity and functional therapeutic success.

Fig.23 Synergy of Scale & Precision. (Creative Biolabs AI)

Synergy of Scale & Precision
By pairing 1011 library depth with multi-parameter cell-native panning, we isolate high-specificity binders that recognize native conformations not just denatured proteins.

Fig.24 Functional-First Strategy. (Creative Biolabs AI)

Functional-First Strategy
We prioritize Mechanism of Action (MoA) from day one. Integrated cell assays for agonism, antagonism, and internalization ensure your leads translate into in vivo efficacy.

Fig.25 De-risked Developability. (Creative Biolabs AI)

De-risked Developability
Eliminate downstream failures early. Our libraries use validated human frameworks and in silico liability screening to filter out PTM, aggregation, and stability issues at the hit stage.

Fig.26 Rapid, Transparent Timelines. (Creative Biolabs AI)

Rapid, Transparent Timelines
Go from project design to functional IgG candidates in as little as 10 weeks. With radical transparency, you get full access to NGS clustering and raw assay data at every milestone.

Fig.27 Mastery of Complex Targets. (Creative Biolabs AI)

Mastery of Complex Targets
Whether it's GPCRs, ion channels, or multi-subunit complexes, our specialized yeast and phage display protocols mitigate off-target binding and unlock "undruggable" epitopes.

Fig.28 Scientific Partnership. (Creative Biolabs AI)

Scientific Partnership
Every project is managed by a dedicated PhD-level scientist. We provide milestone-based billing, clear decision gates, and expert consultation to navigate challenging screening landscapes.

Customize Your Package - Get Pricing

Inquiry & Contact

Creative Biolabs delivers functional, developable anti–cell-based target antibodies by uniting premier premade libraries with cell-native, multi-parameter screening for fast, transparent, and de-risked for downstream success.

Include in your inquiry (checklist):

FAQ

  1. What is the typical timeline for a cell-based screening project?

    A typical project runs 10-16 weeks from design to IgG pilot-expression panel, depending on target complexity and assay scope.

  2. What are the starting requirements?

    We typically require the target information you could offer, and a validated cell line expressing the target. If you don't have a cell line, our team can assist with engineering one as part of the project scope.

  3. What deliverables do we receive and who owns them?

    You receive sequences, ranked binders, and a full technical report.

  4. Can you customize the functional assays?

    We design the screening cascade around your desired mechanism of action. We can incorporate custom cell-based assays, including signaling, reporter assays, internalization, and ADCC/CDC readouts.


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us